InnoCare TYK2 inhibitor soficitinib meets Phase II endpoint in vitiligo
InnoCare Pharma has reported that the Phase II portion of its adaptive Phase II/III trial of soficitinib (ICP-332) in non-segmental vitiligo met its primary endpoint, with both dose cohorts delivering statistically significant reductions in facial disease burden compared with placebo.
At Week 24, patients receiving soficitinib 80 mg once daily showed a least-squares mean percent change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) of 38.8%, while those on 120 mg once daily achieved 41.2%. The placebo arm recorded a 2.2% improvement over the same period. Both active-dose comparisons were statistically significant at P<0.0001. The company reported no new safety signals, describing the tolerability profile as consistent with previous clinical work on the compound.
The compound and its broader programme
Soficitinib is an oral, selective inhibitor of TYK2, a non-receptor tyrosine kinase that sits within the JAK-STAT signalling axis central to several inflammatory and autoimmune pathways. InnoCare is developing the drug across a dermatology-heavy indication set that includes atopic dermatitis, psoriasis, nodular prurigo, and chronic spontaneous urticaria, alongside vitiligo. The breadth of that programme reflects a broader industry thesis: a single well-tolerated oral TYK2 inhibitor with a clean safety profile could address multiple chronic skin conditions that currently rely on injectable biologics or older JAK inhibitors with wider selectivity profiles.
Dr Jasmine Cui, co-founder, chairwoman and chief executive of InnoCare, said soficitinib is "expected to provide an innovative treatment option with superior efficacy, a better safety profile and more convenient administration for patients with vitiligo." The claim of superior efficacy relative to existing options has not yet been tested in a head-to-head trial, and the phrase reflects the company's positioning rather than a regulatory determination.
The trial will now proceed to its Phase III portion, with full efficacy and safety data earmarked for presentation at forthcoming international scientific congresses and peer-reviewed publication. The company did not provide a timeline for Phase III completion or projected regulatory submissions.
Market context
Vitiligo affects an estimated 0.5% to 2% of the global population and until recently had limited approved pharmacological options beyond topical treatments. The landscape shifted in 2022 when the FDA approved ruxolitinib cream, a topical JAK1/JAK2 inhibitor from Incyte, as the first drug indicated specifically for vitiligo repigmentation. The emergence of oral TYK2-selective agents represents the next wave of development, with several companies pursuing the target across immunodermatology indications.
The selectivity argument for TYK2 over broader JAK inhibition has become commercially significant since the FDA added class-wide boxed warnings to JAK inhibitors in 2021, covering risks including serious infections, malignancy, and cardiovascular events. TYK2-selective compounds, which avoid JAK1, JAK2, and JAK3, have been positioned by developers as potentially cleaner in this regard, though long-term safety data in large populations remain limited. Bristol Myers Squibb's deucravacitinib, approved for plaque psoriasis in 2022, provided the first regulatory validation of the TYK2-selective approach.
InnoCare is dual-listed in Hong Kong and on Shanghai's STAR Market, and already has three approved drugs on the market, giving it a commercial infrastructure that could support soficitinib's eventual launch. Investors will be watching for Phase III enrolment updates and the first look at full Phase II data at a major dermatology congress as near-term catalysts.